0.5ZnO@Cu5.4O nanoparticle for regulates the expression of GSDMB and targeted therapy of tumor.

IF 6 2区医学 Q1 ONCOLOGY

Cancer Cell International Pub Date : 2025-06-28 DOI:10.1186/s12935-025-03874-z

Hao Zhang, Guoyan Liu

引用次数: 0

Abstract

GSDMB, a key protein in pyroptosis, is closely linked to various diseases. Nanomaterials can target and regulate specific pathways. Herein, we report a simple and efficient one-step method to develop multi-enzyme nanoparticles capable of suppressing GSDMB expression. 0.5ZnO@Cu5.4O can inhibit GSDMB, a capability that neither ZnO nor Cu5.4O possesses. ZnO@Cu5.4O with different ratios also exhibits varying inhibitory effects. The 0.5ZnO@Cu5.4O can be cleared quickly in vivo, ensuring biocompatibility. Additionally, 0.5ZnO@Cu5.4O significantly inhibits tumor progression, offering promising avenues for clinical cancer therapy, and the development of gene-regulating nanoparticles.

Abstract Image

查看原文本刊更多论文

0.5ZnO@Cu5.4O纳米颗粒用于调节GSDMB的表达和肿瘤的靶向治疗。

GSDMB是焦亡的关键蛋白，与多种疾病密切相关。纳米材料可以靶向和调节特定的途径。在此，我们报告了一种简单有效的一步方法来开发能够抑制GSDMB表达的多酶纳米颗粒。0.5ZnO@Cu5.4O可以抑制GSDMB，这是ZnO和Cu5.4O都不具备的能力。不同比例的ZnO@Cu5.4O也表现出不同的抑制效果。0.5ZnO@Cu5.4O在体内可快速清除，保证生物相容性。此外，0.5ZnO@Cu5.4O显著抑制肿瘤进展，为临床癌症治疗和基因调控纳米颗粒的开发提供了有希望的途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell International ONCOLOGY-

CiteScore

10.90

自引率

1.70%

发文量

360

审稿时长

1 months

期刊介绍： Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.